ACAD on XNAS, Health Care, Acadia Pharmaceuticals Inc., job postings
Measures activity, not value. Not investment advice.
Quarterly revenue rose 23% to $342.3M and 12-month profit rose 39%, but shares are down 25% in a year.
WatchFree cash flow was $82M over 12 months, well below reported profit
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $342.3M, net income $53.5M.
31 Dec 2021RevenueNet incomeNet losstallest bar $342.3M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$342.3M
$53.5M
30 Jun 2026
$308.0M
$31.5M
31 Mar 2026
$268.1M
$3.6M
31 Dec 2025
$284.0M
$273.6M
30 Sep 2025
$278.6M
$71.8M
30 Jun 2025
$264.6M
$26.7M
31 Mar 2025
$244.3M
$19.0M
31 Dec 2024
$259.6M
$143.7M
30 Sep 2024
$250.4M
$32.8M
30 Jun 2024
$242.0M
$33.4M
31 Mar 2024
$205.8M
$16.6M
31 Dec 2023
$231.0M
$45.8M
30 Sep 2023
$211.7M
-$65.2M
30 Jun 2023
$165.2M
$1.1M
31 Mar 2023
$118.5M
-$43.0M
31 Dec 2022
$136.5M
-$41.7M
30 Sep 2022
$130.7M
-$27.2M
30 Jun 2022
$134.6M
-$34.0M
31 Mar 2022
$115.5M
-$113.1M
31 Dec 2021
$130.8M
-$43.1M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$1.2B
$1.0B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+15%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$362.2M
$261.2M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$2.12
$1.55
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
90.5%
91.9%
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
10.2%
23.0%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
30.1%
24.9%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
31.4%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$82.0M
$197.8M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$976.4M
$847.0M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$976.4M (net cash)
-$847.0M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$8.03
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
8.2
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
2.5
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
1.6
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
2.1
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$69K
bought $0, sold $69K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
0%
346 13F filers vs 346
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
96%
166.4M shares held by 13F filers (30 Sep 2026) of 172.8M outstanding (28 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
4.8%
8.3M shares sold short (30 Oct 2026) of 172.8M outstanding (28 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
5.9
8.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-8.5%
9.1M shares sold short in the report before, 8.3M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
46%
46% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 47%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
35
Tracked since 20 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 20 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+23%
$342.3M vs $278.6M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$2.3M
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
20
20 articles in the last 7 days; its usual week has 5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
4.0×
20 articles in the last 7 days; its usual week has 5.
Price $17.11 on 20 Nov 2026, -25% over 12 months (12-month range $16.50 to $30.57)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $2.5M in the last 12 months (the 12 months before: -$2.5M).Revenue per quarter. Revenue $342.3M in the latest quarter, +23% on a year earlier.Capital spending per quarter. Capital spending $1.2M in the latest quarter, +220% on a year earlier.Institutional holders (13F filers). 346 13F filers reported holding it in the latest 13F quarter, +8.5% on a year earlier.Lobbying spend. Lobbying spend: $2.3M published in the last 12 months, +5.9% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $130.8M, +8.1% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $115.5M, +8.4% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $134.6M, +17% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $130.7M, -0.7% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $136.5M, +4.4% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $118.5M, +2.6% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $165.2M, +23% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $211.7M, +62% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $231.0M, +69% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $205.8M, +74% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $242.0M, +46% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $250.4M, +18% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $259.6M, +12% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $244.3M, +19% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $264.6M, +9.3% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $278.6M, +11% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $284.0M, +9.4% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $268.1M, +9.7% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $308.0M, +16% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $342.3M, +23% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $0, -100% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $0, -100% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $0; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $0; public on 1 Mar 2023
Quarter ended 31 Dec 2023: $0; public on 29 Feb 2024
Quarter ended 30 Sep 2024: $70K; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $453K; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $0; public on 8 May 2026
Quarter ended 30 Jun 2025: $297K; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $388K, +454% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Mar 2026: $5.2M; public on 8 May 2026
Quarter ended 30 Jun 2026: $5.1M, +1613% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $1.2M, +220% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 224; public on 14 Feb 2022
31 Mar 2022 report: 250; public on 16 May 2022
30 Jun 2022 report: 234; public on 15 Aug 2022
30 Sep 2022 report: 202; public on 14 Nov 2022
31 Dec 2022 report: 210; public on 14 Feb 2023
31 Mar 2023 report: 218; public on 15 May 2023
30 Jun 2023 report: 219; public on 14 Aug 2023
30 Sep 2023 report: 226; public on 14 Nov 2023
31 Dec 2023 report: 258; public on 14 Feb 2024
31 Mar 2024 report: 254; public on 15 May 2024
30 Jun 2024 report: 249; public on 14 Aug 2024
30 Sep 2024 report: 248; public on 14 Nov 2024
31 Dec 2024 report: 285; public on 14 Feb 2025
31 Mar 2025 report: 305; public on 15 May 2025
30 Jun 2025 report: 295; public on 14 Aug 2025
30 Sep 2025 report: 319; public on 14 Nov 2025
31 Dec 2025 report: 322; public on 17 Feb 2026
31 Mar 2026 report: 330; public on 15 May 2026
30 Jun 2026 report: 346; public on 14 Aug 2026
30 Sep 2026 report: 346; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $200K published
Quarter from 1 Jul 2022: $540K published
Quarter from 1 Oct 2022: $260K published
Quarter from 1 Jan 2023: $370K published
Quarter from 1 Apr 2023: $390K published
Quarter from 1 Jul 2023: $230K published
Quarter from 1 Oct 2023: $180K published
Quarter from 1 Jan 2024: $240K published
Quarter from 1 Apr 2024: $250K published
Quarter from 1 Jul 2024: $450K published
Quarter from 1 Oct 2024: $220K published
Quarter from 1 Jan 2025: $510K published
Quarter from 1 Apr 2025: $440K published
Quarter from 1 Jul 2025: $500K published
Quarter from 1 Oct 2025: $750K published
Quarter from 1 Jan 2026: $590K published
Quarter from 1 Apr 2026: $600K published
Quarter from 1 Jul 2026: $700K published
Quarter from 1 Oct 2026: $440K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $342.3M (30 Sep 2026), 1.3× its normal quarter; higher than 100% of its own history.
Quarterly capital spending jump: spent $5.1M on capital projects in the quarter ended 30 Jun 2026, 17× the same quarter last year Public on 6 Aug 2026.
35 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 31%, Legal, policy & compliance 14%, Program & project management 14%, Research & science 14%.
Reported lobbying spend: $440K in Q3 2026, $700K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
31 Dec 2025
Ended
LMH Strategic Solutionsfor Acadia Pharmaceuticals
General Medicare and Medicaid Issues.; Prescription drug payment reform. Pharmaceutical supply chain.Medicare/Medicaid, Pharmacy
Two or more unrelated kinds of records unusual within 30 days
28 Jan 2025confirmed
Confirmed across sources Institutional holdings and Lobbying and Short interest and volume
Acadia Pharmaceuticals(ACAD): reported $510K of lobbying spend for the quarter ended 31 Dec 2024, 2.1× the same quarter last year; it also had 17.1M shares sold short in the 15 Jan 2025 report, 2.1× the same report last year; and it saw 51 13F filers open a new position in the quarter ended 31 Dec 2024, 1.1× the same quarter last year. Three unrelated kinds of activity within 29 days.
Lobbying: Lobbying on a new issue, became public on 20 Jan 2025
Lobbying: Lobbying spend jump, became public on 20 Jan 2025
Short interest and volume: Short interest spike, became public on 28 Jan 2025
Institutional holdings: Many funds opening a new position, became public on 14 Feb 2025
The quarter ended 31 Dec 2024 against the 8 quarters before it.
this quarterearliernormal: $245KSee the evidence (4 changes)
Lobbying: Lobbying on a new issue became public on 20 Jan 2025
Acadia Pharmaceuticals lobbying on a new issue.
New
['TAX']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6272795
Lobbying: Lobbying spend jump became public on 20 Jan 2025
Acadia Pharmaceuticals reported $510K of lobbying spend for the quarter ended 31 Dec 2024, 2.1× the same quarter last year.
This period
$510K (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$245K
Typical spread (median absolute deviation)
$45K
How far from its usual level
+4.0
Same quarter last year
$240K
History used
2,284 days
the quarter ended 31 Dec 20248 earlier quartersnormal: $245K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
Short interest and volume: Short interest spike became public on 28 Jan 2025
Acadia Pharmaceuticals had 17.1M shares sold short in the 15 Jan 2025 report, 2.1× the same report last year.
This period
17.1M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
10.6M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+3.7
Same report last year
8.1M
History used
2,574 days
the 15 Jan 2025 report24 earlier reportsnormal: 10.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Feb 2025
Acadia Pharmaceuticals saw 51 13F filers open a new position in the quarter ended 31 Dec 2024, 1.1× the same quarter last year.
This period
51 (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
31.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+5.3
Same quarter last year
48
History used
4,110 days
the quarter ended 31 Dec 20248 earlier quartersnormal: 31.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
5 Mar 2024confirmed
Confirmed across sources Institutional holdings and Filings + Financials
Acadia Pharmaceuticals(ACAD): saw 48 13F filers open a new position in the quarter ended 31 Dec 2023, 2.1× the same quarter last year, while it reported revenue of $231.0M for the quarter ended 31 Dec 2023, 1.7× the same quarter last year. Two unrelated kinds of activity within 14 days.
Institutional holdings: Many funds opening a new position, became public on 14 Feb 2024
Financials: Quarterly revenue change, became public on 5 Mar 2024
The quarter ended 31 Dec 2023 against the 8 quarters before it.
this quarterearliernormal: 30.5See the evidence (2 changes)
Institutional holdings: Many funds opening a new position became public on 14 Feb 2024
Acadia Pharmaceuticals saw 48 13F filers open a new position in the quarter ended 31 Dec 2023, 2.1× the same quarter last year.
This period
48 (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
30.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+4.7
Same quarter last year
23
History used
3,744 days
the quarter ended 31 Dec 20238 earlier quartersnormal: 30.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Financials: Quarterly revenue change became public on 5 Mar 2024
Acadia Pharmaceuticals reported revenue of $231.0M for the quarter ended 31 Dec 2023, 1.7× the same quarter last year.
This period
$231.0M (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
$132.7M
Typical spread (median absolute deviation)
$9.0M
How far from its usual level
+7.4
Same quarter last year
$136.5M
History used
4,932 days
the quarter ended 31 Dec 20238 earlier quartersnormal: $132.7M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
3 Mar 2020confirmed
Confirmed across sources Institutional holdings and Filings + Financials
Acadia Pharmaceuticals(ACAD): saw 57 13F filers open a new position in the quarter ended 31 Dec 2019, 2.1× the same quarter last year, while it reported revenue of $98.3M for the quarter ended 31 Dec 2019, 1.7× the same quarter last year. Two unrelated kinds of activity within 14 days.
Institutional holdings: Many funds opening a new position, became public on 14 Feb 2020
Financials: Quarterly revenue change, became public on 3 Mar 2020
The quarter ended 31 Dec 2019 against the 8 quarters before it.
this quarterearliernormal: 31See the evidence (2 changes)
Institutional holdings: Many funds opening a new position became public on 14 Feb 2020
Acadia Pharmaceuticals saw 57 13F filers open a new position in the quarter ended 31 Dec 2019, 2.1× the same quarter last year.
This period
57 (the quarter ended 31 Dec 2019)
Normal quarter (median of 8 earlier)
31
Typical spread (median absolute deviation)
3.5
How far from its usual level
+5.0
Same quarter last year
27
History used
2,283 days
the quarter ended 31 Dec 20198 earlier quartersnormal: 31
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Financials: Quarterly revenue change became public on 3 Mar 2020
Acadia Pharmaceuticals reported revenue of $98.3M for the quarter ended 31 Dec 2019, 1.7× the same quarter last year.
This period
$98.3M (the quarter ended 31 Dec 2019)
Normal quarter (median of 8 earlier)
$58.9M
Typical spread (median absolute deviation)
$7.0M
How far from its usual level
+3.8
Same quarter last year
$59.6M
History used
3,471 days
the quarter ended 31 Dec 20198 earlier quartersnormal: $58.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
23 Oct 2026Filings change
filed a director or officer change (8-K item 5.02), its first in 90 days.
Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.
spent $5.1M on capital projects in the quarter ended 30 Jun 2026, 17× the same quarter last year.
Same quarter last year: $297K; its normal quarter is $342K.
See the evidence
This period
$5.1M (the quarter ended 30 Jun 2026)
Normal quarter (median of 8 earlier)
$342K
Typical spread (median absolute deviation)
$308K
How far from its usual level
+4.7
Same quarter last year
$297K
History used
3,743 days
the quarter ended 30 Jun 20268 earlier quartersnormal: $342K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
spent $5.2M on capital projects in the quarter ended 31 Mar 2026, against none in the same quarter last year.
See the evidence
This period
$5.2M (the quarter ended 31 Mar 2026)
Normal quarter (median of 6 earlier)
$184K
Typical spread (median absolute deviation)
$184K
How far from its usual level
+5.0
Same quarter last year
$0
History used
4,565 days
the quarter ended 31 Mar 20266 earlier quartersnormal: $184K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
saw 57 13F filers open a new position in the quarter ended 31 Mar 2025, 1.4× the same quarter last year.
Same quarter last year: 40; its normal quarter is 32.5.
See the evidence
This period
57 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
32.5
Typical spread (median absolute deviation)
3.5
How far from its usual level
+4.7
Same quarter last year
40
History used
4,200 days
the quarter ended 31 Mar 20258 earlier quartersnormal: 32.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 51 13F filers open a new position in the quarter ended 31 Dec 2024, 1.1× the same quarter last year.
Same quarter last year: 48; its normal quarter is 31.5.
See the evidence
This period
51 (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
31.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+5.3
Same quarter last year
48
History used
4,110 days
the quarter ended 31 Dec 20248 earlier quartersnormal: 31.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported $510K of lobbying spend for the quarter ended 31 Dec 2024, 2.1× the same quarter last year; it also had 17.1M shares sold short in the 15 Jan 2025 report, 2.1× the same report last year; and it saw 51 13F filers open a new position in the quarter ended 31 Dec 2024, 1.1× the same quarter last year. Three unrelated kinds of activity within 29 days.
See the evidence (4 changes)
Lobbying: Lobbying on a new issue became public on 20 Jan 2025
Acadia Pharmaceuticals lobbying on a new issue.
New
['TAX']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6272795
Lobbying: Lobbying spend jump became public on 20 Jan 2025
Acadia Pharmaceuticals reported $510K of lobbying spend for the quarter ended 31 Dec 2024, 2.1× the same quarter last year.
This period
$510K (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$245K
Typical spread (median absolute deviation)
$45K
How far from its usual level
+4.0
Same quarter last year
$240K
History used
2,284 days
the quarter ended 31 Dec 20248 earlier quartersnormal: $245K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
Short interest and volume: Short interest spike became public on 28 Jan 2025
Acadia Pharmaceuticals had 17.1M shares sold short in the 15 Jan 2025 report, 2.1× the same report last year.
This period
17.1M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
10.6M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+3.7
Same report last year
8.1M
History used
2,574 days
the 15 Jan 2025 report24 earlier reportsnormal: 10.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Feb 2025
Acadia Pharmaceuticals saw 51 13F filers open a new position in the quarter ended 31 Dec 2024, 1.1× the same quarter last year.
This period
51 (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
31.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+5.3
Same quarter last year
48
History used
4,110 days
the quarter ended 31 Dec 20248 earlier quartersnormal: 31.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
28 Jan 2025Short interest and volume change
had 17.1M shares sold short in the 15 Jan 2025 report, 2.1× the same report last year.
Same report last year: 8.1M; its normal report is 10.6M.
See the evidence
This period
17.1M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
10.6M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+3.7
Same report last year
8.1M
History used
2,574 days
the 15 Jan 2025 report24 earlier reportsnormal: 10.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported $510K of lobbying spend for the quarter ended 31 Dec 2024, 2.1× the same quarter last year.
Same quarter last year: $240K; its normal quarter is $245K.
See the evidence
This period
$510K (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$245K
Typical spread (median absolute deviation)
$45K
How far from its usual level
+4.0
Same quarter last year
$240K
History used
2,284 days
the quarter ended 31 Dec 20248 earlier quartersnormal: $245K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
reported $450K of lobbying spend for the quarter ended 30 Jun 2024, 2.0× the same quarter last year.
Same quarter last year: $230K; its normal quarter is $245K.
See the evidence
This period
$450K (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$245K
Typical spread (median absolute deviation)
$15K
How far from its usual level
+8.4
Same quarter last year
$230K
History used
2,100 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $245K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
saw 48 13F filers open a new position in the quarter ended 31 Dec 2023, 2.1× the same quarter last year, while it reported revenue of $231.0M for the quarter ended 31 Dec 2023, 1.7× the same quarter last year. Two unrelated kinds of activity within 14 days.
See the evidence (2 changes)
Institutional holdings: Many funds opening a new position became public on 14 Feb 2024
Acadia Pharmaceuticals saw 48 13F filers open a new position in the quarter ended 31 Dec 2023, 2.1× the same quarter last year.
This period
48 (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
30.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+4.7
Same quarter last year
23
History used
3,744 days
the quarter ended 31 Dec 20238 earlier quartersnormal: 30.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Financials: Quarterly revenue change became public on 5 Mar 2024
Acadia Pharmaceuticals reported revenue of $231.0M for the quarter ended 31 Dec 2023, 1.7× the same quarter last year.
This period
$231.0M (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
$132.7M
Typical spread (median absolute deviation)
$9.0M
How far from its usual level
+7.4
Same quarter last year
$136.5M
History used
4,932 days
the quarter ended 31 Dec 20238 earlier quartersnormal: $132.7M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
5 Mar 2024Financials change
reported revenue of $231.0M for the quarter ended 31 Dec 2023, 1.7× the same quarter last year.
Same quarter last year: $136.5M; its normal quarter is $132.7M.
See the evidence
This period
$231.0M (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
$132.7M
Typical spread (median absolute deviation)
$9.0M
How far from its usual level
+7.4
Same quarter last year
$136.5M
History used
4,932 days
the quarter ended 31 Dec 20238 earlier quartersnormal: $132.7M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
saw 48 13F filers open a new position in the quarter ended 31 Dec 2023, 2.1× the same quarter last year.
Same quarter last year: 23; its normal quarter is 30.5.
See the evidence
This period
48 (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
30.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+4.7
Same quarter last year
23
History used
3,744 days
the quarter ended 31 Dec 20238 earlier quartersnormal: 30.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $211.7M for the quarter ended 30 Sep 2023, 1.6× the same quarter last year.
Same quarter last year: $130.7M; its normal quarter is $131.2M.
See the evidence
This period
$211.7M (the quarter ended 30 Sep 2023)
Normal quarter (median of 8 earlier)
$131.2M
Typical spread (median absolute deviation)
$4.3M
How far from its usual level
+6.1
Same quarter last year
$130.7M
History used
4,840 days
the quarter ended 30 Sep 20238 earlier quartersnormal: $131.2M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported $370K of lobbying spend for the quarter ended 31 Dec 2022, 1.9× the same quarter last year.
Same quarter last year: $200K; its normal quarter is $215K.
See the evidence
This period
$370K (the quarter ended 31 Dec 2022)
Normal quarter (median of 8 earlier)
$215K
Typical spread (median absolute deviation)
$10K
How far from its usual level
+7.2
Same quarter last year
$200K
History used
1,553 days
the quarter ended 31 Dec 20228 earlier quartersnormal: $215K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
Fires on an 8-K with item 5.02 after 90 days without one.
Showing the newest 40 of 100 entries; narrow the window or the kind of data to see older ones.
Not listed: 296 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001070494
Ticker
ACAD
Domain
acadia.com
Employer name
Acadia Pharmaceuticals Inc. (1 unverified)
Hq location
CA|SAN DIEGO|92130 (1 unverified)
Lobbying client
acadia pharmaceuticals, peck madigan jones on behalf of acadia pharmaceuticals
Name
Acadia Pharmaceuticals (France) SAS, Acadia Pharmaceuticals (Germany) GmbH, Acadia Pharmaceuticals GmbHAcadia Pharmaceuticals Holdings Inc.Acadia Pharmaceuticals (Canada) Inc, Acadia Pharmaceuticals Inc. and 8 more
Uei
D79ND8GZR3E6
Wikidata
Q4671580
Wikipedia
Acadia Pharmaceuticals
DOL H-1B labor condition applications and PERM certifications5 data points10 May 2021 to 10 May 2021
Federal lobbying disclosures (LDA)9 records, 99 data points2 Jul 2018 to 30 Sep 2026
SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)155 records5 Jan 2016 to 4 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1141 data points31 Dec 2008 to 28 Oct 2026
SEC Form 4 insider transactions188 records, 416 data points8 Jan 2016 to 30 Oct 2026
FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4176 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards12 data points12 May 2011 to 19 Jan 2018
Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026